Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) is dedicated to supporting innovative projects and programs that enhance the knowledge and understanding of diseases and technological advancements. Their commitment is toward advancing scientific awareness and technologies for public health and welfare in various therapeutic areas of interest. They aim to further scientific progress while ensuring that the projects they support maintain independent control over their goals and dissemination of knowledge.
The External Collaborative Research (ECR) program by Boehringer Ingelheim is designed to support collaboration on studies in distinct therapeutic areas by offering drug and/or financial backing. Key areas of interest include Cardio-Renal-Metabolic systems, with a focus on the effects and utilization of empagliflozin, real-world implementation of guideline-based management, treatment pathways, provider impact, and transition-of-care models. In Mental Health, the program targets the evaluation of patient assessment and treatment landscapes in conditions such as Schizophrenia, PTSD, and Major Depressive Disorder, along with the role of digital therapeutics. Dermatology research is encouraged on the natural course, comorbidities, patient-reported outcomes, therapy limitations, pathogenesis, and management of Generalized Pustular Psoriasis (GPP). Oncology-focused research is sought on Soft Tissue Sarcoma, Biliary Tract Cancer, and Non-Small Cell Lung Cancer, with an emphasis on real-world data and novel treatment combinations. For Respiratory conditions, studies on Asthma and COPD are encouraged, focusing on pharmacological management, healthcare resource utilization, and effectiveness of specific treatments, alongside research on Fibrosing Interstitial Lung Diseases (ILD) about diagnostic tools, disease management, and non-pharmacologic care.